BioPharm America™ to be held September 19–21, 2012 at the Westin Boston Waterfront in Boston, MA, will host the first SciBX Innovation in Drug Discovery & Development Summit in partnership with Nature Publishing Group and BioCentury Publications Inc. The focus of the SciBX Summit will be the development of a white paper “Roadmap” on Macrocycles and Constrained Peptides-Challenges and Applications. BioPharm America is organized by EBD Group, the leading partnering firm for the life science industry, in collaboration with the Massachusetts Biotechnology Council (MassBio).
The SciBX Summit will consist of a panel discussion featuring stakeholders in the space from biotech, pharma, the venture community and academia. These panelists will convene with the goal of providing the foundation for the Roadmap document capturing the landscape and the challenges, opportunities and necessary next steps in the field that would facilitate its advancement to the next phase of development. This final report will be complemented with insights gained during the SciBX Summit taking place at BioPharm America.
“The SciBX Summit is a great addition to our event as it will give our attendees a chance to participate in the discovery process through an active discussion with the ‘think tank’ represented by the panel speakers. It’s a firsthand look into biopharma’s innovation process in formulating a roadmap leading to the next level of development for these compounds in advance of the white paper,” said Carola Schropp, President of EBD Group.
“This Summit will focus the discussion around the opportunities afforded by macrocycles and constrained peptides in the area of targeting intracellular protein-protein interactions, their potential for improved oral bioavailability and related benefits,” said Gaspar Taroncher-Oldenburg, PhD, Managing Editor and Associate Publisher of SciBX.
Speakers on the SciBX Summit panel, to be held Friday, September 21 at 9:00 am, includeBruce Booth of Atlas Venture; Spiros Liras of Pfizer; Barry Morgan of GlaxoSmithKline;Patrick Reid of PeptiDream Inc.; Tomi Sawyer of Aileron Therapeutics; and Gregory Verdine of Harvard Medical School/Third Rock Ventures.
“The SciBX Innovation Summit will be an extraordinary opportunity to discuss state-of-the-art science and emerging breakthroughs in medicine during the BioPharm America 2012 conference,” said Tomi Sawyer, Chief Scientific Officer at Aileron Therapeutics. “As part of the team pioneering the development of Stapled Peptide drugs, I’m particularly excited to help create the SciBX Roadmap on Macrocycles and Constrained Peptides which should provide significant insights to understand key advances in both drug discovery and innovative technologies.”
“Expanding tractable chemical space available to challenging targets such as protein-protein interactions will be beneficial to the drug development pipeline, obviously, and this panel will utilize the expertise of the group to review the problems and current status for bringing peptide derived drugs to the market,” said Barry Morgan, VP, Molecular Discovery & Research at GlaxoSmithKline.
The SciBX Innovation in Drug Discovery & Development Summit at BioPharm America is the inaugural summit. The goal of this program is to capture the interest of all those invested in innovation in the life sciences, and in particular in areas in which there is obvious excitement at the confluence of academia, VCs, biotech and pharma.
The full BioPharm America 2012 program can be viewed online at
Registration information for BioPharm America can be found by going to
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Additional links and information:
Follow BioPharm America 2014 on Twitter: twitter.com/ebdgroup (hashtag: #BPA14)
Or join the Life Science Partnering group on partnering360® to kick off your partnering activities before BioPharm America, and throughout the year. partnering360 is a dynamic network of life science industry experts that will enable you to continue the dialogue from your partneringONE meetings at events and identify and connect with new partners anytime, year-round. Join the vibrant community of life science companies on partnerning360 today.